Liu Yang, Wang Gang, Xu Wei-Guo, Song Ji-Ning, Yang Xiao-Qing, Wang Wen-Ya
Department of ICU Tangshan Gongren Hospital, Tangshan 063000, China.
Zhonghua Yi Xue Za Zhi. 2009 Jun 23;89(24):1687-9.
To detect the differential expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) count in benign and malignant breast lesions to clarify the correlation of VEGF expression with the occurrence and progression of breast cancer and angiogenesis.
Immunohistochemistry (SP method) was used to examine the expression of VEGF and MVD count in 88 intra-operatively harvested samples of invasive ductal breast carcinoma, 25 samples of breast carcinoma in situ, 15 samples of atypical breast hyperplasia and 100 samples of benign breast lesions obtained.
The positive rate of VEGF in invasive ductal breast carcinoma group was 70.5% and it was significantly higher than those of benign breast lesions, atypical breast hyperplasia and breast carcinoma in situ groups ( 22.0%, 33.3% and 56.0% respectively, P = 0.000). The positive rate of VEGF with lymph node metastasis was higher than that without lymph node metastasis (P = 0.015). The positive rate of VEGF in Stages II b- III was higher than that in Stages I - II a (P = 0.006). The positive rate of VEGF in C-erbB-2 positive group was higher than that in C-erbB-2 negative group (P = 0.016). An elevated expression of VEGF was observed as the tissue differentiation degree increased (P = 0.017). The MVD value of invasive ductal breast carcinoma group was 23 +/- 15 and it was significantly higher than those of benign breast lesions, atypical breast hyperplasia and breast carcinoma in situ groups (14 +/- 4, 18 +/- 4 and 20 +/- 6 respectively, P = 0.000). In invasive ductal breast carcinoma group, a significant higher MVD value was observed as the tissue differentiation degree increased (P = 0.006). The MVD value in VEGF positive group was higher than that in VEGF negative group (P = 0.000). In invasive ductal breast carcinoma, the MVD count increased significantly with the elevated expression of VEGF (P = 0.000).
In invasive ductal breast carcinoma, angiogenesis and metastasis are mediated mainly by VEGF. The expressions of VEGF and MVD may be two of reference predictors for biological behaviors of breast carcinoma The occurrence and progression of breast cancer might be correlated with the expression of VEGF. The VEGF-targeting antiangiogenic therapy is expected to become a new therapeutic modality for C-erbB-2 positive patients.
检测血管内皮生长因子(VEGF)在乳腺良恶性病变中的表达差异及微血管密度(MVD)计数,以阐明VEGF表达与乳腺癌发生、发展及血管生成的关系。
采用免疫组织化学(SP法)检测88例手术切除的浸润性导管癌、25例原位癌、15例非典型乳腺增生及100例乳腺良性病变组织中VEGF的表达及MVD计数。
浸润性导管癌组VEGF阳性率为70.5%,显著高于乳腺良性病变、非典型乳腺增生及原位癌组(分别为22.0%、33.3%和56.0%,P = 0.000)。有淋巴结转移的VEGF阳性率高于无淋巴结转移者(P = 0.015)。Ⅱb - Ⅲ期VEGF阳性率高于Ⅰ - Ⅱa期(P = 0.006)。C - erbB - 2阳性组VEGF阳性率高于C - erbB - 2阴性组(P = 0.016)。随着组织分化程度增加,VEGF表达升高(P = 0.017)。浸润性导管癌组MVD值为23±15,显著高于乳腺良性病变、非典型乳腺增生及原位癌组(分别为14±4、18±4和20±6,P = 0.000)。在浸润性导管癌组,随着组织分化程度增加,MVD值显著升高(P = 0.006)。VEGF阳性组MVD值高于VEGF阴性组(P = 0.000)。在浸润性导管癌中,MVD计数随VEGF表达升高而显著增加(P = 0.000)。
在浸润性导管癌中,血管生成和转移主要由VEGF介导。VEGF和MVD的表达可能是乳腺癌生物学行为的参考预测指标。乳腺癌的发生和发展可能与VEGF表达有关。针对VEGF的抗血管生成治疗有望成为C - erbB - 2阳性患者的一种新治疗方式。